GLP-1 News for Thursday, November 14, 2024

Research indicates that the protein PGC-1α plays a crucial role in exercise-induced weight loss by regulating metabolism and energy consumption. Targeting this protein may lead to new weight loss medications, providing additional options for those struggling with obesity. However, the study is in early stages, and further exploration is needed to determine its practical applications in fitness and weight loss treatments.

Recent research indicates that GLP-1 medications like Ozempic and Wegovy may help reduce problem drinking among individuals with alcohol use disorder. A study involving nearly 228,000 Swedish participants found that those taking semaglutide had a 36% lower likelihood of hospitalization, while liraglutide showed a 28% reduction. Additionally, semaglutide was associated with a decreased risk of suicide. These findings suggest a potential benefit of GLP-1 drugs over traditional anti-alcoholism treatments, highlighting the need for further clinical trials to confirm these results.

GLP-1 receptor agonists (RAs) are increasingly being integrated into preconception care by fertility specialists due to their potential benefits for weight loss and reproductive health, particularly for women with conditions like polycystic ovary syndrome (PCOS). While these medications can aid in weight management, comprehensive care including nutritional and mental health support is essential, especially as patients transition off the drugs before conception. Ongoing research is needed to fully understand the long-term effects of GLP-1s on pregnancy outcomes and the safety for both men and women preconception. Conversations about weight and family planning should be approached sensitively by healthcare providers to foster positive patient relationships.

Researchers at the University of California, San Francisco, have discovered a method to convert white fat cells into beige fat cells, which can burn calories more effectively. This transformation is linked to the protein KLF-15, and by reducing its production, ordinary white fat can become beige without relying on stem cells. This breakthrough could lead to new weight-loss drugs with fewer side effects and longer-lasting benefits, potentially revolutionizing obesity treatment.

A recent study indicates that drugs like Ozempic can not only treat diabetes but also significantly reduce the risk of developing it in overweight or obese adults with pre-diabetes. While some doctors advocate for lifestyle changes as first-line treatments, the effectiveness and cost of these medications raise questions about their necessity and insurance coverage. Concerns include the potential for weight regain after stopping the medication and the accessibility of these drugs for patients with pre-diabetes, especially as insurance companies tighten coverage policies.

A study presented at the American Heart Association Scientific Sessions 2024 found that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly reduce mortality, myocardial infarction (MI), and recurrent stroke in patients with ischemic stroke. The research involved 7,044 participants and indicated that those using these medications had a lower risk of adverse cardiovascular events, reinforcing their preventive role in cardiovascular disease, particularly for individuals with obesity or heart failure.

Positive results from a phase III trial of semaglutide for metabolic dysfunction-associated steatohepatitis (MASH) are prompting Novo Nordisk to expand the GLP-1 agonist's indications in the U.S. and Europe, as the field anticipates more innovative therapies.

Ozempic, a GLP-1 receptor agonist, shows promise in protecting kidney function in individuals with type 2 diabetes and chronic kidney disease (CKD), as well as in those without diabetes but at risk of CKD. Research indicates it reduces the risk of kidney disease events, mortality, and cardiovascular issues. However, it is not FDA-approved for CKD treatment, and further studies are needed to assess its effects across diverse populations. While it can improve kidney health, caution is advised due to potential risks of kidney injury, particularly in those with acute kidney injury.

Recent research indicates that semaglutide, the active ingredient in Ozempic, may significantly reduce the risk of developing Alzheimer's disease by up to 70% in patients with type 2 diabetes compared to other anti-diabetic medications. The study highlights a potential link between type 2 diabetes and dementia, suggesting shared risk factors. While the exact mechanisms remain unclear, semaglutide's anti-inflammatory properties may contribute to its neuroprotective effects. Further research is needed to establish causation and validate these findings before clinical application for Alzheimer's prevention.

In a 3-year follow-up of the SURMOUNT-1 trial, patients with obesity lost an average of 22.9% of their body weight with the highest dose of tirzepatide (Zepbound), alongside improvements in cardiometabolic health markers. Participants reported enhanced quality of life, but weight regain occurred after discontinuation of the medication. The study highlighted the importance of combining medication with lifestyle interventions for effective diabetes management and obesity treatment. Adverse events were primarily mild to moderate, with gastrointestinal issues being the most common.

A Cedars-Sinai study reveals a significant rise in prescriptions for GLP-1 receptor agonists (GLP-1RAs), originally for Type 2 diabetes but increasingly used for obesity treatment. These medications help regulate blood sugar and control appetite, showing potential for long-term weight loss and cardiovascular benefits. Emerging research also suggests possible mental health improvements associated with GLP-1RAs. However, challenges such as high costs and side effects remain, necessitating further research to optimize their use and accessibility in healthcare.

Daily oral semaglutide (25 mg) resulted in significant weight loss compared to placebo in individuals with overweight or obesity, showing efficacy similar to larger oral doses and weekly injectables. The OASIS 4 trial indicated an average weight loss of 13.6% for the semaglutide group versus 2.2% for placebo, with improvements in quality of life and cardiometabolic risk factors. Most adverse events were gastrointestinal, but the safety profile aligned with existing GLP-1 receptor agonists, suggesting oral semaglutide may be a viable treatment option for those preferring oral medication.

Gan & Lee Pharmaceuticals announced positive Phase 1 results for its oral GLP-1 receptor agonist GZR18, showing an average weight reduction of 4.16% in healthy participants after two weeks. The drug demonstrated favorable pharmacokinetics supporting once-daily dosing and was well-tolerated, with gastrointestinal reactions as the most common adverse events. GZR18 is currently in global Phase 1 clinical development and has not yet been approved in China.

Hofseth BioCare's ProGo, a soluble protein hydrolysate derived from Atlantic salmon, may activate the GLP-1 receptor, offering a natural weight management solution. Clinical studies indicate it can lead to 6-7% fat loss and improved metabolic markers, with benefits observed at doses as low as 4 g per day. The product shows promise for women's health, particularly for menopausal women. Additionally, the company’s salmon oil product, OmeGo, is being researched for its effects on lung health and sleep.

Novo Nordisk maintains its expectation that the experimental obesity drug CagriSema will achieve a 25% weight loss, similar to existing GLP-1 drugs. The company plans to release late-stage trial data by the end of 2024, which is crucial for its obesity investment strategy amid competition. Analysts predict significant share price fluctuations based on the trial results. Additionally, Novo is conducting further studies on psychiatric side effects related to another obesity treatment, monlunabant, which is currently in a Phase 2b trial.

Modular Medical's pre-clinical GLP-1 proof of concept study showed a 17.1% weight loss at 28 days with a basal-bolus delivery system, outperforming semaglutide in glucose control. The study suggests that this pump delivery could offer a smoother weight loss initiation and enhanced glucose management compared to traditional GLP-1 treatments. The company plans to advance to human trials with its MODD1 device, aiming to capture market share in the competitive GLP-1 market.

A recent study highlights that significant weight loss from Ozempic and similar drugs may lead to considerable muscle mass loss, with fat-free mass loss ranging from 25-39% over 32-76 weeks. This muscle loss, which is greater than typical age-related decline, poses health risks such as increased falls, reduced mobility, and heart health issues. Researchers emphasize the importance of managing muscle loss through adequate protein intake and exercise as consumers pursue weight loss.

A recent study indicates that semaglutide, a GLP-1 weight loss drug, may reduce knee pain in obese individuals with osteoarthritis primarily through weight loss rather than the medication itself. Participants who took semaglutide lost significantly more weight and reported greater reductions in knee pain compared to those on a placebo. However, experts emphasize that weight loss is the key factor in alleviating knee pain, and further research is needed to determine if semaglutide has direct effects on pain relief independent of weight loss. Patients experiencing knee pain should consult healthcare providers for appropriate treatment options.

The FDA has added a warning to all GLP-1 receptor agonists regarding the risk of pulmonary aspiration during general anesthesia or deep sedation. This warning is due to reports of aspiration in patients who had residual gastric contents despite following fasting guidelines. The updated labels do not provide specific recommendations for mitigating this risk, and recent guidance from the American Society of Anesthesiologists allows most patients to continue their GLP-1 medications up to the day of surgery, with a liquid diet advised 24 hours prior, depending on individual circumstances.

A recent study published in JAMA Ophthalmology suggests a potential link between semaglutide, a GLP-1 receptor agonist used for diabetes and obesity, and an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION). The study, led by Dr. Joseph F. Rizzo III, evaluated a cohort of patients and found a higher occurrence of NAION among those treated with semaglutide. Experts emphasize the need for caution in interpreting these findings, as the association requires further investigation and may be influenced by underlying diabetes risk factors. While the risk of NAION is considered rare, it is essential to monitor patients with preexisting ocular conditions when prescribing semaglutide.

A study found that semaglutide, a GLP-1 receptor agonist, does not increase the risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients with type 2 diabetes or obesity. Researchers analyzed data from a large cohort and confirmed no significant association between semaglutide use and NAION across various follow-up periods. Limitations include the retrospective nature of the study and potential misclassification of NAION cases.

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least 100 hospitalizations and 10 deaths.

Pendulum Therapeutics has launched a GLP-1 Probiotic designed to enhance metabolic health by stimulating GLP-1 production, which may help reduce appetite and cravings. The product aims to assist consumers in maintaining a healthy weight.

Novo Nordisk announced a potential successor to Ozempic called CagriSema, which combines semaglutide with an amylin and calcitonin receptor antagonist. Initial trials showed an average weight loss of 15.6% over 32 weeks, with expectations that further trials may demonstrate over 25% weight loss. The company plans to release results from late-stage trials in late 2024 and early 2025, and anticipates a safety profile similar to existing GLP-1 drugs.

Research indicates a rising demand for GLP-1 drugs, with significant disparities in usage based on income, sex, and geography. Key findings show that higher income correlates with increased GLP-1 use, with female patients constituting nearly 65% of users. Usage varies by state, with the Southeast showing higher rates compared to the Western U.S. Additionally, age impacts access, particularly for younger and older populations, with only 0.2% of obese Americans under 18 prescribed GLP-1s and limited Medicare coverage for seniors.

Ozempic and similar weight-loss medications are surrounded by misinformation and controversy, reflecting historical misconceptions about weight management. Business Insider producer Elizabeth McCauley examines scientific literature and consults experts to clarify the truths about these medications.

Novo Nordisk is set to introduce a stronger Ozempic successor while sales of its weight loss drug Wegovy continue to exceed expectations. Hims & Hers will offer a generic version of liraglutide next year. The FDA is proposing to ban oral phenylephrine in OTC medications due to ineffectiveness as a decongestant. Other highlights include Zealand Pharma's experimental drug showing fewer side effects, Novo Nordisk's collaboration with Ascendis Pharma for a monthly weight-loss drug, and Viking Therapeutics reporting promising results for its oral weight-loss pill.

Novo Nordisk reported mixed results for its GLP-1 drugs Ozempic and Wegovy in the third quarter, with Ozempic generating 29.8 billion kroner but falling short of expectations, while Wegovy saw a significant 79% sales increase to 17.3 billion kroner. Overall, Novo's sales rose 21% year-over-year to 71.3 billion kroner, but still missed analyst forecasts. The company has adjusted its 2024 sales growth outlook to 23%-27%. Supply challenges and competition from compounding pharmacies remain concerns, despite improvements in manufacturing capacity.

The document discusses the transformation of healthcare through venture capital, focusing on GLP-1 drugs and AI, featuring insights from Peter van der Velden of Lumira Ventures. It includes a link to a related podcast episode for further exploration of the topic.

Altimmune's drug candidate, pemvidutide, aims to address muscle loss associated with weight loss treatments, particularly benefiting women over 50. Clinical results show pemvidutide has a lower percentage of lean muscle loss compared to competitors, with an average weight loss of 15.6% over 48 weeks. With FDA approval for Phase 3 trials, Altimmune is positioned for significant market potential, and analysts project a 157% upside in its stock.

The use of weight loss drugs like Ozempic and Wegovy has more than doubled, coinciding with a 25% decline in bariatric surgeries from 2022 to 2023, according to a study by Harvard researchers. While these medications offer new treatment options for obesity-related complications, barriers such as high costs, side effects, insurance denials, and access disparities remain significant challenges. The study highlights concerns about socioeconomic stratification affecting access to these medications, particularly among minority patients.

The global oral proteins and peptides market is projected to grow from USD 7.38 billion in 2024 to USD 20.36 billion by 2029, at a CAGR of 22.5%. Key drivers include the rising demand for oral peptides in treating chronic diseases like diabetes, increased R&D investments, and advancements in drug delivery technologies. Semaglutide is the leading molecule in this market, particularly for managing type-2 diabetes. The US dominates the market due to its strong biopharmaceutical sector and investments in research. The report also highlights challenges such as high development costs and regulatory hurdles, while identifying opportunities in the growing demand for non-invasive treatments.

The ObesityWeek conference highlighted significant developments in weight-loss drugs, with a shift towards oral medications from companies like Viking Therapeutics and AstraZeneca. Analysts anticipate a move from GLP-1 to amylin-based treatments, which may offer fewer side effects. The focus on percentage weight loss as a success metric is being questioned, with calls for more comprehensive health assessments. Compounded drugs are increasingly used due to access issues with name-brand medications. The broader health benefits of obesity treatment are being recognized, linking it to conditions like heart disease and mental health.

The ongoing review of Novo Holdings' $16.5 billion acquisition of Catalent raises concerns about competition, particularly regarding Eli Lilly's reliance on Catalent for GLP-1 drug production. While Novo asserts that Catalent has no role in manufacturing Lilly's GLP-1 competitors, Lilly's CEO expressed concerns about the implications of the merger on competition and production capacity. Regulatory bodies, including the FTC and EU, are scrutinizing the deal, with decisions expected by the end of the year.

Novo Nordisk, the maker of Ozempic and Wegovy, reported a 21% profit increase in Q3 and raised its operating profit forecast to 21%-27% at constant exchange rates. The company narrowed its sales estimate to 23%-27%. Following the news, Novo Nordisk shares rose 6% in Copenhagen, outperforming competitors after Donald Trump's election win.

Wellful Inc., the owner of Nutrisystem and Jenny Craig, is in debt talks as it struggles with significant losses attributed to competition from weight-loss drugs like Ozempic. The company is consulting with experts and creditors regarding its $550 million debt due in 2028, following a downgrade in its credit ratings due to a 30% decline in earnings in the first half of 2024. Other companies in the weight-loss sector are facing similar challenges, with Weight Watchers' stock plummeting nearly 90% this year.

Medicaid spending on GLP-1 medications has increased by over 500% since 2019, according to researchers from KFF. The report highlights significant growth in expenditures related to these treatments over the past five years.

Few state Medicaid programs currently cover GLP-1 drugs for obesity due to their high cost, with only thirteen programs offering coverage as of August 2024. However, prescriptions and spending on GLP-1s have surged, increasing over 400% and 500% respectively from 2019 to 2023. Many states are considering adding coverage, citing potential long-term health benefits and cost savings from reduced obesity-related diseases. Despite the growing interest, nearly two-thirds of Medicaid payers are concerned about the financial impact on state budgets.

In the U.S. Veterans Affairs Medical System, Black patients and those of Asian or Native American ancestry were less likely to receive semaglutide than white patients for diabetes or weight loss, study leader Dr. Rebecca Tisdale of the VA Palo Alto Health Care System in Menlo Park, California, said. Semaglutide is sold by Novo Nordisk as Ozempic for treatment of type 2 diabetes and as Wegovy for weight management.

A 58-year-old nurse in Scotland, Susan McGowan, died after taking two doses of the weight-loss drug tirzepatide, also known as Mounjaro. Her death, attributed to multiple organ failure and septic shock with the drug listed as a contributing factor, marks the first official case linked to the medication in the U.K. Tirzepatide is a GLP-1 receptor agonist that suppresses appetite but can cause severe side effects. While regulators maintain that the benefits outweigh the risks, a second suspected death related to the drug is under investigation.

Employer health insurance premiums are projected to increase by 7% to 9% in 2025 due to rising adoption of GLP-1 drugs for weight loss, increased catastrophic claims, and other cost pressures. Employees are advised to carefully review their health care options during open enrollment, as many may need to adjust their expectations regarding benefits and costs. High-deductible health plans (HDHPs) could offer some cost savings, but employees should proactively assess their coverage needs, especially as these cost pressures are expected to continue into 2026.

Ozempic, a diabetes medication, faces multiple lawsuits as users report severe side effects, including paralysis, blindness, and teeth loss. Plaintiffs claim that manufacturers Novo Nordisk and Eli Lilly did not adequately disclose these risks. Many affected individuals, like Monica Church and Jacqueline Barber, experienced debilitating health issues after using the drug. As the popularity of GLP-1 agonists for weight loss rises, the number of lawsuits continues to increase, with patients seeking justice for the lack of risk disclosure.

Off-label use of compounded semaglutide has been linked to approximately 10 deaths and 100 hospitalizations in the U.S., prompting Novo Nordisk to urge the FDA to prohibit its compounding due to significant safety concerns. The complexities of semaglutide's formulation increase the risk of adverse events, particularly when compounded improperly. The document also discusses controversies surrounding tirzepatide, including a lawsuit against the FDA for its sudden removal from the drug shortage list and concerns over counterfeit products. Pharmacists are highlighted as crucial in educating patients about the risks of compounded medications and advocating for FDA-approved treatments.

GLP-1 agonists may be associated with a small risk of nonarteritic anterior ischemic optic neuropathy (NAION), but more research is needed to establish causation. Informed consent is crucial when prescribing these medications, especially for patients with preexisting ischemic optic neuropathy. Discussions with patients should emphasize that the risk factors for NAION overlap with those for obesity and diabetes, framing the risk as low versus low. Individual risk tolerance and specific circumstances, such as monocularity, should guide the risk-benefit analysis.

The rise in global obesity is linked to the consumption of ultra-processed foods (UPFs), which constitute a significant portion of energy intake in many countries. UPFs are associated with increased risks of obesity, cardiovascular diseases, and type 2 diabetes (T2D). The drug Ozempic, originally for diabetes, shows efficacy in weight loss and is projected to see substantial sales growth. However, addressing the root causes of obesity through food policy changes is essential for public health and could reduce reliance on pharmaceutical solutions.

Ozempic, a medication for diabetes and weight loss, can cause side effects including "Ozempic butt," characterized by sagging skin in the buttocks after significant weight loss. This occurs due to rapid fat loss outpacing skin elasticity. Individuals at higher risk include those with rapid weight loss, lower muscle mass, and older age. To manage this side effect, strength training, a protein-rich diet, hydration, topical treatments, and microneedling are recommended. Preventative measures include gradual weight loss, a balanced diet, and maintaining skin hydration.

Psyllium husk, a soluble fiber supplement, is gaining attention as a potential alternative to Ozempic for weight management, but it does not work in the same way. While it may support weight management by promoting fullness and aiding blood sugar control, it is not a substitute for Ozempic's effects. Experts recommend consulting a doctor before use, especially for those on medications, and suggest starting with small doses to avoid gastrointestinal discomfort.

Ozempic and similar GLP-1 drugs, initially approved for diabetes and obesity, are being explored for treating various conditions such as colorectal cancer, osteoarthritis, substance abuse, brain diseases, skin conditions, sleep apnea, and polycystic ovary syndrome. These medications work by mimicking the GLP-1 hormone, reducing inflammation, and improving insulin sensitivity, which may lead to significant health benefits beyond weight loss. However, users report side effects, and off-label use should be approached with caution under medical supervision.

Chioma Nnadi, editor of British Vogue, expressed concern over the return of skinny models, attributing it partially to the use of Ozempic, a drug popular among celebrities for weight loss. She highlighted the lack of body diversity in fashion, noting that most runway models are still sample sizes, which limits representation. A report showed that 94.9% of looks were size US 0-4, with only 0.8% being plus-size. Nnadi hopes this trend will not continue and emphasizes the need for more inclusive representation in the industry.

Dr. Spencer Nadolsky discusses the promising future of GLP-1 medications like Ozempic for weight loss, highlighting their effectiveness in achieving significant weight loss results compared to traditional methods. He emphasizes the importance of combining these medications with lifestyle changes, such as resistance training, to mitigate potential muscle loss. While acknowledging the high costs and insurance challenges associated with GLP-1 medications, he advocates for their use under medical supervision and expresses optimism for their wider availability and affordability in the future.

Amy Kane, who lost 160 pounds using Ozempic, shared her experience with excess skin after weight loss on TikTok, highlighting societal shaming for both weight struggles and medication use. Experts confirm that significant weight loss often results in excess skin, regardless of the method. Kane, who has PCOS and insulin resistance, emphasizes her improved health and new relationship with food, planning to undergo a tummy tuck to address her concerns about body image.

The ongoing shortage of GLP-1 drugs, driven by increased demand for weight loss and diabetes management, has significantly impacted access for patients with type 2 diabetes. Reports indicate that the shortage began in late 2022 and continues into 2024, with disparities in access exacerbated by insurance coverage issues and the off-label use of these medications for weight loss. Physicians are exploring alternative strategies to help patients navigate these shortages, while manufacturers are working to increase production and improve delivery methods.

The FDA has declared that the shortage of GLP-1 medications like Wegovy and Ozempic is over, but this may lead to higher costs and reduced access to these drugs. Compounding pharmacies, which provide cheaper alternatives, may face limitations as the FDA removes drugs from the shortage list. A lawsuit has been filed against the FDA for not adequately considering the implications of this decision, as many patients may struggle to fill prescriptions for the brand-name versions. The demand-driven nature of these shortages complicates the situation, potentially leaving patients without affordable options.

Access to GLP-1 medications is influenced by care site, payer type, and demographics, with factors such as female sex, older age, and high-deductible plans associated with higher initiation rates. Conversely, exclusive provider organizations and health maintenance plans correlate with lower initiation rates. The study highlights the need to address care gaps for individuals with obesity, particularly those without diabetes, who are at risk for cardiometabolic issues.

Lottie Moss warns against using Ozempic for weight loss after suffering severe side effects, including nausea and a seizure due to dehydration. She emphasizes that the medication is not worth the risk unless medically necessary, sharing her harrowing experience to caution others. While some have had positive outcomes with Ozempic, Lottie’s story highlights the potential dangers associated with its misuse.

Semaglutide, the active ingredient in Ozempic, may help alleviate perimenopause symptoms such as weight gain, mood swings, and fatigue. It aids in weight management by curbing appetite and enhancing fullness, and improves mood and energy levels by addressing insulin resistance. Additionally, weight loss from semaglutide may reduce hot flashes and night sweats. Women experiencing persistent symptoms despite lifestyle changes or hormone therapy should consider discussing semaglutide with their doctor, while being aware of potential side effects.

Ozempic, a medication for type 2 diabetes, has seen an increase in reported overdoses, primarily due to dosing errors. While technically possible, overdosing is unlikely with proper instruction. Side effects of taking too much Ozempic can include nausea, vomiting, stomach pain, and more severe issues like acute pancreatitis. To prevent overdosing, patients should communicate clearly with their prescribing doctors and avoid self-dosing without guidance.

Health officials warn against compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, due to reports of at least 100 hospitalizations and 10 deaths. Novo Nordisk emphasizes that only their manufactured semaglutide is safe, as compounded drugs lack FDA approval and may pose risks. Semaglutide is popular for its effectiveness in weight loss, blood sugar control, and cardiovascular benefits, but potential side effects should be discussed with a healthcare provider.

GLP-1 medications like Ozempic may not guarantee weight loss for everyone. If cravings persist and less than 5% weight loss isn't achieved in 12 weeks, consult a healthcare provider about adjusting dosage or switching medications. Factors influencing weight loss include dosage, body mass index, and adherence to lifestyle changes. If results are lacking, optimizing medication and lifestyle strategies or considering alternative therapies may be necessary.

Dr. Lotte Knudsen, the scientist behind Ozempic, is now researching potential treatments for Alzheimer's disease using GLP-1 analogs. Her studies suggest that drugs like Ozempic may help prevent cognitive decline and reduce the risk of dementia, especially in individuals with type 2 diabetes. Despite promising findings, challenges remain in understanding the underlying causes of dementia and the long-term effects of these treatments. Knudsen aims to further investigate the role of GLP-1 in neurodegenerative diseases while addressing concerns about the safety and efficacy of these medications.

Semaglutide, marketed as Ozempic and Rybelsus, has gained popularity in India for managing diabetes and aiding weight loss. Doctors report positive outcomes in diabetes control and weight management, although costs and side effects can be barriers. The drug mimics the hormone GLP-1, slowing digestion and reducing appetite. While it shows promise, it is primarily prescribed for diabetes management, not as a first-line weight loss solution. Patient experiences vary, with some achieving significant weight loss while others face challenges. The high cost of semaglutide remains a significant hurdle for many patients in India.

Ozempic, a drug known for its weight loss effects, has raised concerns due to side effects like vomiting and dehydration. Micro-dosing Ozempic aims to reduce these risks by using lower-than-standard doses, potentially offering appetite control and metabolic support. While some doctors advocate for this approach, caution is advised due to the lack of clinical studies on micro-dosing. It's essential to monitor for side effects and consider long-term health impacts, as well as to maintain a focus on nutrition and exercise for sustainable weight management.

Smoothie King has launched a new GLP-1 Support Menu aimed at users of GLP-1 medications like Ozempic, featuring smoothies high in protein and fiber with no added sugars. Created in collaboration with dietitian Molly Kimball, the menu includes five smoothies designed to support weight loss and metabolic health, available at all 1,200 locations nationwide.

In May, newly reported survey data from KFF showed that one in eight adults (12%) have tried a GLP-1 agonist — the class of drugs that includes Ozempic. So, it's no surprise that several wellness- and supplement-focused brands have launched products intended to meet the moment, though each of the products discussed in this piece positions itself slightly differently and uses different ingredients. In addition to supplements created to "mimic" the effects of drugs like Ozempic, there is also a growing segment of products to support users of GLP-1 medications, both in the supplement space and in grocery aisles.